Platform for generating safe cell therapeutics
View Patent ↗Provided herein are cytoplasts, compositions comprising cytoplasts, methods of using cytoplasts, and methods of treating a subject, such as providing benefits to a healthy or unhealthy subject, or treating or diagnosing a disease or condition in a subject. In some embodiments, methods of treating a subject include: administering to the subject a therapeutically effective amount of a composition comprising a cytoplast. Also, provided herein are compositions (e.g., pharmaceutical compositions) that include a cytoplast. Also, provided herein are kits comprising instructions for using the compositions or methods.
1. A method of administering a vaccine composition to a subject, the method comprising administering to the subject a cell without a nucleus comprising one or more intracellular organelles that synthesizes or secretes a vaccine composition in an absence of the nucleus, wherein the cell is not a red blood cell.
2. The method of claim 1 , wherein the vaccine composition is for an influenza virus.
3. The method of claim 1 , wherein the vaccine composition is for a Severe Acute Respiratory Syndrome coronavirus.
4. The method of claim 1 , wherein the cell without the nucleus further comprises a therapeutic agent.
5. The method of claim 4 , wherein the therapeutic agent comprises a cytokine, or a portion thereof.
6. The method of claim 5 , wherein the cytokine comprises interleukin 10 or a variant thereof, or interleukin 12 or a variant thereof.
7. The method of claim 1 , wherein the vaccine composition is secreted by the cell without the nucleus.
8. The method of claim 1 , wherein the cell further comprises a homing receptor that is specific to a ligand expressed on one or more cells in lung tissue of the subject.
9. The method of claim 8 , wherein the homing receptor comprises P-selectin glycoprotein ligand-1.
10. The method of claim 8 , wherein the homing receptor comprises C-C Motif Chemokine Receptor 2.
11. The method of claim 8 , wherein the homing receptor comprises C-X-C Motif Chemokine Receptor 4.
12. The method of claim 1 , wherein the cell further comprises a homing receptor that is specific to a ligand expressed on one or more cells in lymph tissue of the subject.
13. The method of claim 12 , wherein the homing receptor comprises C-X-C chemokine receptor type 3.
14. The method of claim 12 , wherein the homing receptor comprises CD44 antigen.
15. The method of claim 12 , wherein the homing receptor comprises C-C chemokine receptor type 7.
16. The method of claim 1 , wherein the vaccine composition is exogenous to the cell.
17. The method of claim 1 , wherein the cell has a diameter comprising at most about 100 micrometers.
18. The method of claim 1 , wherein the cell is viable for 24 hours or longer following removal of the cell from cryohybernation or cryopreservation.
19. The method of claim 1 , further comprising removing the cell from cryohybernation or cryopreservation prior to administering the cell to the subject.